Moderna (Brazil) Performance
| M1RN34 Stock | BRL 12.95 0.44 3.52% |
The company secures a Beta (Market Risk) of -0.16, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Moderna are expected to decrease at a much lower rate. During the bear market, Moderna is likely to outperform the market. At this point, Moderna has a negative expected return of -0.58%. Please make sure to verify Moderna's jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if Moderna performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Moderna has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 2.6 B | |
| Total Cashflows From Investing Activities | -8.5 B |
Moderna |
Moderna Relative Risk vs. Return Landscape
If you would invest 1,950 in Moderna on September 12, 2024 and sell it today you would lose (655.00) from holding Moderna or give up 33.59% of portfolio value over 90 days. Moderna is generating negative expected returns and assumes 3.5727% volatility on return distribution over the 90 days horizon. Simply put, 31% of stocks are less volatile than Moderna, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Moderna Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moderna's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moderna, and traders can use it to determine the average amount a Moderna's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1635
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | M1RN34 |
Estimated Market Risk
| 3.57 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.58 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Moderna is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moderna by adding Moderna to a well-diversified portfolio.
Moderna Fundamentals Growth
Moderna Stock prices reflect investors' perceptions of the future prospects and financial health of Moderna, and Moderna fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moderna Stock performance.
| Return On Equity | 0.84 | |||
| Return On Asset | 0.35 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.62 % | |||
| Current Valuation | 387.59 B | |||
| Shares Outstanding | 7.68 B | |||
| Price To Book | 4.44 X | |||
| Price To Sales | 19.80 X | |||
| Revenue | 18.47 B | |||
| EBITDA | 13.54 B | |||
| Cash And Equivalents | 7.99 B | |||
| Cash Per Share | 19.80 X | |||
| Total Debt | 599 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 4.65 X | |||
| Cash Flow From Operations | 13.62 B | |||
| Earnings Per Share | 7.47 X | |||
| Total Asset | 24.67 B | |||
About Moderna Performance
By analyzing Moderna's fundamental ratios, stakeholders can gain valuable insights into Moderna's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Moderna has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moderna has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1800 people.Things to note about Moderna performance evaluation
Checking the ongoing alerts about Moderna for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moderna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moderna generated a negative expected return over the last 90 days | |
| Moderna has high historical volatility and very poor performance |
- Analyzing Moderna's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moderna's stock is overvalued or undervalued compared to its peers.
- Examining Moderna's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moderna's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moderna's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moderna's stock. These opinions can provide insight into Moderna's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |